INV-101 / Innovo Therap - LARVOL DELTA

A FIRST-IN-CLASS GLYCOGEN PHOSPHORYLASE INHIBITOR INV-101: PRECLINICAL EFFICACY IN COLITIS MODELS AND PHASE 1 SAFETY AND PHARMACOKINETICS IN HEALTHY VOLUNTEERS (UEGW 2026) - No abstract available

P1 data • PK/PD data • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology

Inovoterapeutics, Autoimmune Disease New Drug 'INV-101' Confirmed Safety in US Phase 1 [Google translation] (HIT News) - P1 | N=48 | NCT06938204 | Sponsor: Innovo Therapeutics, Inc. | "Inovatorepeutics....announced on the 9th that its autoimmune disease treatment new drug candidate 'INV-101', which the company is developing, confirmed excellent safety and pharmacodynamic characteristics through a phase 1 clinical trial conducted in the United States....Excellent safety and tolerability were secured without serious adverse events (SAEs) or dose-limiting toxicities (DLTs) in all dose groups, and the pharmacokinetic analysis results confirmed that the drug was safe enough to be administered orally once a day and could be taken without separate monitoring.....Inovoterapeutics plans to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) in the first half of next year and begin a global phase 2 clinical trial. The study was conducted with the support of the National Drug Development Fund."

IND • New P2 trial • P1 data • Immunology

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Innovo Therapeutics, Inc.

New P1 trial

First in Human, Single Ascending Dose Study (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Innovo Therapeutics, Inc.

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis